Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 347,829,312
  • Shares Outstanding, K 2,407,623
  • Annual Sales, $ 85,159 M
  • Annual Income, $ 35,153 M
  • EBIT $ 13,952 M
  • EBITDA $ 21,438 M
  • 60-Month Beta 0.51
  • Price/Sales 4.00
  • Price/Cash Flow 10.40
  • Price/Book 4.88

Options Overview Details

View History
  • Implied Volatility 20.09% ( -1.30%)
  • Historical Volatility 16.37%
  • IV Percentile 93%
  • IV Rank 68.21%
  • IV High 23.61% on 01/10/25
  • IV Low 12.53% on 05/09/24
  • Put/Call Vol Ratio 0.60
  • Today's Volume 28,679
  • Volume Avg (30-Day) 35,315
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 425,235
  • Open Int (30-Day) 384,747

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 2.00
  • Number of Estimates 8
  • High Estimate 2.10
  • Low Estimate 1.94
  • Prior Year 2.29
  • Growth Rate Est. (year over year) -12.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
140.68 +2.89%
on 01/10/25
147.25 -1.70%
on 12/16/24
-1.87 (-1.28%)
since 12/13/24
3-Month
140.68 +2.89%
on 01/10/25
166.75 -13.19%
on 10/15/24
-16.85 (-10.43%)
since 10/14/24
52-Week
140.68 +2.89%
on 01/10/25
168.85 -14.27%
on 09/04/24
-17.64 (-10.86%)
since 01/12/24

Most Recent Stories

More News
Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly's drag

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks kept indexes in check

META : 594.25 (-2.31%)
NVDA : 131.76 (-1.10%)
AAPL : 233.28 (-0.48%)
C : 73.50 (+1.00%)
$SPX : 5,842.91 (+0.11%)
JPM : 247.47 (+1.33%)
JNJ : 144.75 (+0.19%)
HEES : 90.29 (+105.48%)
M : 14.02 (-3.71%)
$IUXX : 20,757.41 (-0.13%)
URI : 729.86 (+5.91%)
SIG : 58.00 (-21.66%)
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference

The JP Morgan Healthcare Conference, which is being held in San Francisco this year, has been much more active than last year. Among some of the top news at the conference were M&A deal announcements by...

ITCI : 126.89 (-0.24%)
JNJ : 144.75 (+0.19%)
LLY : 744.91 (-6.59%)
GSK : 32.08 (-1.90%)
What Lies Ahead for Dow ETF in Q4 Earnings?

The Dow Jones Industrial Average Index is performing better than the other two major indices amid the rise in Treasury yields and the tech sell-off. This is especially true as the blue-chip index shed...

JPM : 247.47 (+1.33%)
INTC : 19.20 (unch)
JNJ : 144.75 (+0.19%)
GS : 571.53 (+1.52%)
DOW : 40.08 (+1.03%)
DIA : 425.15 (+0.52%)
UNH : 543.74 (+0.48%)
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share in cash,...

ITCI : 126.89 (-0.24%)
SDZNY : 42.2400 (+0.05%)
JNJ : 144.75 (+0.19%)
Stock market today: Gains for oil producers and drops for Big Tech leave Wall Street mixed

U.S. stock indexes were split as gains for oil-and-gas producers helped offset drops for Nvidia and other Big Tech companies

MSTR : 342.17 (+4.19%)
ALL : 186.81 (+2.34%)
NVDA : 131.76 (-1.10%)
META : 594.25 (-2.31%)
AAPL : 233.28 (-0.48%)
CVX : 156.90 (+1.00%)
BAC : 45.78 (+1.60%)
$SPX : 5,842.91 (+0.11%)
JPM : 247.47 (+1.33%)
MS : 124.62 (+0.51%)
JNJ : 144.75 (+0.19%)
HHH : 77.84 (-0.99%)
J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by purchasing Intra-Cellular Therapies

ITCI : 126.89 (-0.24%)
$SPX : 5,842.91 (+0.11%)
JNJ : 144.75 (+0.19%)
$DOWI : 42,518.28 (+0.52%)
$IUXX : 20,757.41 (-0.13%)
Johnson & Johnson To Buy Drugmaker Intra-Cellular For $14.6 Billion

Johnson & Johnson (JNJ) has announced that it plans to acquire drugmaker Intra-Cellular Therapies (ITCI), ...

JNJ : 144.75 (+0.19%)
Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism

ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million in...

ITCI : 126.89 (-0.24%)
JNJ : 144.75 (+0.19%)
2 Beaten-Down Dividend Stocks to Buy in 2025

Dividend stocks are great for various reasons, and it's even better to invest in them while they are going through a rough patch, provided there are good reasons to believe they will recover. This description...

CVS : 51.57 (+0.10%)
JNJ : 144.75 (+0.19%)
Meet the 15 Dow Jones Stocks That Combined for Over $150 Billion in Dividends in 2024 and Will All Likely Boost Their Payouts Again in 2025

The Dow Jones Industrial Average (DJINDICES: ^DJI) is composed of 30 industry-leading blue-chip businesses that represent the broader market. Many of these companies also pay growing dividends.

AAPL : 233.28 (-0.48%)
CSCO : 59.33 (+0.97%)
KO : 62.04 (+0.63%)
VZ : 38.28 (+0.42%)
CVX : 156.90 (+1.00%)
JPM : 247.47 (+1.33%)
MRK : 99.65 (-1.32%)
JNJ : 144.75 (+0.19%)
MMM : 137.21 (+1.94%)
UNH : 543.74 (+0.48%)
MCD : 281.58 (-0.72%)
MSFT : 415.67 (-0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 147.37
2nd Resistance Point 146.09
1st Resistance Point 145.42
Last Price 144.75
1st Support Level 143.47
2nd Support Level 142.19
3rd Support Level 141.52

See More

52-Week High 168.85
Fibonacci 61.8% 158.09
Fibonacci 50% 154.76
Fibonacci 38.2% 151.44
Last Price 144.75
52-Week Low 140.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar